Immunomodulation of Rat Endometriotic Implant Growth and Protein Production
Version of Record online: 9 MAY 2013
American Journal of Reproductive Immunology
Volume 31, Issue 2-3, pages 151–162, March-April 1994
How to Cite
Nothnick, W. B., Curry, T. E. and Vernon, M. W. (1994), Immunomodulation of Rat Endometriotic Implant Growth and Protein Production. American Journal of Reproductive Immunology, 31: 151–162. doi: 10.1111/j.1600-0897.1994.tb00860.x
- Issue online: 9 MAY 2013
- Version of Record online: 9 MAY 2013
- Accepted December 9, 1993
- immune system;
PROBLEM: The immune system has been implicated in the pathophysiology of endometriosis. To determine if modulation of the immune system influences endometriotic implant growth and protein production, the following experiment was conducted.
METHOD: Female rats with surgically induced endometriosis were treated with either the immunosuppressive agent pentoxifylline (Pent; 5 mg/kg BW; N = 16) or a vehicle (N = 16) for 7 consecutive days, then killed. Twenty-four hours before death, 8 animals from each group were injected intraperitoneally with the immunostimulatory agent lipopolysaccharide (LPS; 200 Hg/kg BW). At death, endometriotic implants were measured and protein production assessed by two-dimensional polyacrylamide gel electrophoresis.
RESULT: Pentoxifylline significantly (P < 0.001) reduced endometriotic implant size (2.15 ± 0.65 mm2 vs. 17.13 ± 1.98 mm2) whereas LPS was without effect (18.32 ± 2.57 mm2 vs. 17.13 ± 1.98 mm2). Pentoxifylline also suppressed production of a portion of the proteins that comprise the implant specific group of proteins, ENDO-2, whereas LPS induced the production of two additional ENDO-2 proteins.
CONCLUSION: Immunomodulatory agents can modulate rat endometriotic implant growth and production of implant-specific proteins.